Table 1 Effect of end-induction MRD on... | American Society of Hematology

Table 1

Effect of end-induction MRD on outcome by therapeutic protocol and NCI risk group

Study/risk group	5-y EFS, % ± SE (no.)
Study/risk group	MRD⁻	MRD⁺ (> .01%)*
9904/SR	95 ± 1 (668)	64 ± 7 (105)
9905/SR	89 ± 2 (464)	59 ± 6 (119)
9905/HR	79 ± 4 (295)	33 ± 8 (74)
9906/HR†	72 ± 5 (161)	34 ± 8 (85)

Study/risk group	5-y EFS, % ± SE (no.)
Study/risk group	MRD⁻	MRD⁺ (> .01%)*
9904/SR	95 ± 1 (668)	64 ± 7 (105)
9905/SR	89 ± 2 (464)	59 ± 6 (119)
9905/HR	79 ± 4 (295)	33 ± 8 (74)
9906/HR†	72 ± 5 (161)	34 ± 8 (85)

P < .001 for all comparisons.

Also includes CNS3 patients, patients with testicular disease, or patients with MLL rearrangements.